No Data
RAINMED-B (02297.HK) held a Board of Directors meeting on March 31 to consider and approve the annual performance.
Globe News reported on March 19 that RAINMED-B (02297.HK) announced that the Board of Directors will hold a meeting on March 31, 2025 (Monday) to consider and approve the annual performance of the company and its subsidiaries for the period ending December 31, 2024, and to publish it, as well as to consider the distribution of a final dividend (if any), and to address Other matters.
The new drug development time is cut in half, diagnoses are more accurate, industry barriers are lowered... AI is transforming the Medical Industry in China.
On February 26, Deutsche Bank Analyst Cyrus Ng released a report stating that the entire Medical Industry in China, from drug development and diagnostics to Hospital management, will benefit from the AI revolution.
The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus
① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.
AI hotspots continue to boost! Most Medical stocks in Hong Kong strengthen, with Micro-invasion Siasun Robot&Automation rising over 20%.
How does Sister Wood perceive this hot topic of AI Medical? What positive impacts will the emergence of DeepSeek bring to the medical field?
Hong Kong stock concept tracking | Medical devices trade-in program attracts institutional attention, clear trend of market recovery.
"Trade-in" is accelerating in the field of medical devices, and various provinces are intensively issuing "feasibility announcements", "project approval announcements" and "tender procurement notices", injecting a dose of "cardiotonic" into the market.
Runmaide-B [02297] is now trading at 0.19 Hong Kong dollars, with a increase of 30.14%.
As of 15:58, Runmaid-B [02297] reported a price of 0.19 Hong Kong dollars, up 0.044 Hong Kong dollars or 30.14% from the closing price of 0.146 Hong Kong dollars yesterday, with a trading volume of 0.0006 million Hong Kong dollars. The highest price today is 0.146 Hong Kong dollars, the lowest price is 0.146 Hong Kong dollars. Based on the closing price of yesterday, the 10-day average price is 0.16 Hong Kong dollars, the 50-day average price is 0.16 Hong Kong dollars. The current P/E ratio is -1.34 times, and the 14-day relative strength index is 28.85.
